布地奈德联合特布他林雾化吸入对AECOPD临床治疗的系统评价

目的 系统评价布地奈德联合特布他林雾化吸入治疗慢性阻塞性肺疾病急性加重期（acute exacerbation of chronicobstructive pulmonary disease,AECOPD）的疗效。方法 检索维普、中国知网、万方、中国生物医学数据库、Pubmed、Embase,检索时间从各数据库建库到2017年12月。纳入文献中干预方式采用布地奈德联合特布他林雾化吸入治疗AECOPD的随机对照试验,由研究员按照预先制定的数据提取表提取数据,最终共纳入随机对照试验论文11篇,共计911例研究对象,其中治疗组460例,对照组451例。对照组为常规治疗;治疗组在对照组治疗基础上,采用布地奈德联合特布他林雾化吸入治疗AECOPD,再采用Cochrane Reviewers Handbook 5.0.2推荐的"偏倚风险评估"工具评价纳入研究质量,运用RevMan 5.2软件进行分析。结果 治疗后,治疗组患者的总有效率明显高于对照组,有统计学差异（P<0.05）,临床效果明显。结论 布地奈德联合特布他林雾化吸入对AECOPD患者的临床治疗效果显著,总有效率提高,血气指标得到良好改善,不良反应出现率降低,提高了患者的生活质量,值得临床推广。

Systematic Review of Budesonide Combined with Terbutaline on the Clinical Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

OBJECTIVE To evaluate the effect of budesonide combined with terbutaline in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD). METHODS The databases such as VIP, CNKI, Wanfang, CBM, Pubmed and Embase were searched. The search time was from the construction of the library to December 2017. In randomized controlled trials, used budesonide combined with terbutaline to treat AECOPD, and the researcher extracted data according to pre-established data extraction form, obtained 11 of randomized controlled trials, a total of 911 subjects, including 460 cases in the treatment group and 451 cases in the control group. The treatment group was given budesonide combined with terbutaline, and the control group was given conventional therapy. The quality of the included studies was assessed by using the "biased risk assessment" tool, which recommended by the Cochrane Reviewers Handbook 5.0.2, and analyzed by RevMan 5.2 software. RESULTS After treatment, the total effective rate of treatment group was significantly higher than the control group, and there were significant differences(P<0.05). CONCLUSION It is significant for the clinical therapeutic effect to use budesonide combined with terbutaline in the treatment of AECOPD. The total effective rate and the blood gas index is improved, and the incidence of adverse reactions is reduced. That can improve the quality of life of patients, is worthy of clinical promotion.